Taysha Gene Therapies Inc (TSHA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 268.10 is considered Overvalued compared with the five-year average of -4.39. The fair price of Taysha Gene Therapies Inc (TSHA) is between 1.14 to 3.29 according to relative valuation method. Compared to the current price of 4.55 USD , Taysha Gene Therapies Inc By Overvalued By 38.46%.

Relative Value

Fair Zone

1.14-3.29

Current Price：4.55

38.46%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Taysha Gene Therapies Inc (TSHA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Taysha Gene Therapies Inc (TSHA) has a current Price-to-Book (P/B) ratio of 6.57. Compared to its 3-year average P/B ratio of 4.32, the current P/B ratio is approximately 51.99% higher. Relative to its 5-year average P/B ratio of 7.61, the current P/B ratio is about -13.72% higher. Taysha Gene Therapies Inc (TSHA) has a Forward Free Cash Flow (FCF) yield of approximately -5.92%. Compared to its 3-year average FCF yield of -41.67%, the current FCF yield is approximately -85.79% lower. Relative to its 5-year average FCF yield of -53.45%, the current FCF yield is about -88.92% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TSHA competitors is 71.79, providing a benchmark for relative valuation. Taysha Gene Therapies Inc Corp (TSHA.O) exhibits a P/S ratio of 268.10, which is 273.45% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TSHA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TSHA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TSHA currently overvalued or undervalued?

Taysha Gene Therapies Inc (TSHA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 268.10 is considered Overvalued compared with the five-year average of -4.39. The fair price of Taysha Gene Therapies Inc (TSHA) is between 1.14 to 3.29 according to relative valuation method. Compared to the current price of 4.55 USD, Taysha Gene Therapies Inc is Overvalued By 38.46%.

What is Taysha Gene Therapies Inc (TSHA) fair value?

TSHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Taysha Gene Therapies Inc (TSHA) is between 1.14 to 3.29 according to relative valuation method.

How does TSHA's valuation metrics compare to the industry average?

The average P/S ratio for TSHA's competitors is 71.79, providing a benchmark for relative valuation. Taysha Gene Therapies Inc Corp (TSHA) exhibits a P/S ratio of 268.10, which is 273.45% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Taysha Gene Therapies Inc (TSHA) as of Mar 02 2026?

As of Mar 02 2026, Taysha Gene Therapies Inc (TSHA) has a P/B ratio of 6.57. This indicates that the market values TSHA at 6.57 times its book value.

What is the current FCF Yield for Taysha Gene Therapies Inc (TSHA) as of Mar 02 2026?

As of Mar 02 2026, Taysha Gene Therapies Inc (TSHA) has a FCF Yield of -5.92%. This means that for every dollar of Taysha Gene Therapies Inc's market capitalization, the company generates -5.92 cents in free cash flow.

What is the current Forward P/E ratio for Taysha Gene Therapies Inc (TSHA) as of Mar 02 2026?

As of Mar 02 2026, Taysha Gene Therapies Inc (TSHA) has a Forward P/E ratio of -12.62. This means the market is willing to pay $-12.62 for every dollar of Taysha Gene Therapies Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Taysha Gene Therapies Inc (TSHA) as of Mar 02 2026?

As of Mar 02 2026, Taysha Gene Therapies Inc (TSHA) has a Forward P/S ratio of 268.10. This means the market is valuing TSHA at $268.10 for every dollar of expected revenue over the next 12 months.

TSHA Valuation